161 related articles for article (PubMed ID: 34051063)
21. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
22. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
de Cárcer G
Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30862113
[TBL] [Abstract][Full Text] [Related]
23. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
24. KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
Duan L; Rai G; Roggero C; Zhang QJ; Wei Q; Ma SH; Zhou Y; Santoyo J; Martinez ED; Xiao G; Raj GV; Jadhav A; Simeonov A; Maloney DJ; Rizo J; Hsieh JT; Liu ZP
Chem Biol; 2015 Sep; 22(9):1185-96. PubMed ID: 26364928
[TBL] [Abstract][Full Text] [Related]
25. Plk1 phosphorylation of Numb leads to impaired DNA damage response.
Shao C; Chien SJ; Farah E; Li Z; Ahmad N; Liu X
Oncogene; 2018 Feb; 37(6):810-820. PubMed ID: 29059161
[TBL] [Abstract][Full Text] [Related]
26. RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.
van der Meer R; Song HY; Park SH; Abdulkadir SA; Roh M
Clin Cancer Res; 2014 Jun; 20(12):3211-21. PubMed ID: 24771642
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms underlying Plk1 polo-box domain-mediated biological processes and their physiological significance.
Lee KS; Park JE; Kang YH; Kim TS; Bang JK
Mol Cells; 2014 Apr; 37(4):286-94. PubMed ID: 24722413
[TBL] [Abstract][Full Text] [Related]
29. Targeting polo-like kinase 1 for cancer therapy.
Strebhardt K; Ullrich A
Nat Rev Cancer; 2006 Apr; 6(4):321-30. PubMed ID: 16557283
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA miR-509 Regulates ERK1/2, the Vimentin Network, and Focal Adhesions by Targeting Plk1.
Liao G; Wang R; Rezey AC; Gerlach BD; Tang DD
Sci Rep; 2018 Aug; 8(1):12635. PubMed ID: 30135525
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of polo-like kinase 1 suppresses microtubule dynamics in MCF-7 cells.
Rashid A; Naaz A; Rai A; Chatterji BP; Panda D
Mol Cell Biochem; 2020 Feb; 465(1-2):27-36. PubMed ID: 31782084
[TBL] [Abstract][Full Text] [Related]
32. Plk1-mediated mitotic phosphorylation of PinX1 regulates its stability.
Wang C; Yu J; Yuan K; Lan J; Jin C; Huang H
Eur J Cell Biol; 2010 Oct; 89(10):748-56. PubMed ID: 20573420
[TBL] [Abstract][Full Text] [Related]
33. G
Giráldez S; Galindo-Moreno M; Limón-Mortés MC; Rivas AC; Herrero-Ruiz J; Mora-Santos M; Sáez C; Japón MÁ; Tortolero M; Romero F
FASEB J; 2017 Jul; 31(7):2925-2936. PubMed ID: 28360195
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
35. Mitotic phosphotyrosine network analysis reveals that tyrosine phosphorylation regulates Polo-like kinase 1 (PLK1).
Caron D; Byrne DP; Thebault P; Soulet D; Landry CR; Eyers PA; Elowe S
Sci Signal; 2016 Dec; 9(458):rs14. PubMed ID: 27965426
[TBL] [Abstract][Full Text] [Related]
36. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
37. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
38. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
39. Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A.
Jang YJ; Ji JH; Choi YC; Ryu CJ; Ko SY
J Biol Chem; 2007 Jan; 282(4):2473-82. PubMed ID: 17121863
[TBL] [Abstract][Full Text] [Related]
40. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
